Abstract
Splenectomy and corticosteroids are the treatment of choice for patients with immune thrombocytopenic purpura (ITP). However, for the 10%–15% of patients who do not respond to conventional therapy, high-dose i.v. IgG can induce life-saving transient responses. The benefits of i.v. IgG have been attributed to Fc receptor blockade; however, the involvement of the individual Fc receptors for IgG (FcγR) in ITP remain to be more completely defined. Recently a mAb, designated mAb H22, which recognizes an epitope on FcγRI (CD64) outside the ligand-binding domain, was humanized. Because mAb H22 is a human IgG1 and FcγRI has a high affinity for human IgG1 antibodies, we predicted that mAb H22 would bind to the FcγRI ligand-binding site through its Fc domain and to its external FcγRI epitope through both Fab domains. These studies demonstrate that mAb H22 blocked FcγRI-mediated phagocytosis of opsonized red blood cells more effectively than an irrelevant IgG. Moreover, cross-linking FcγRI with mAb H22 down-modulated FcγRI expression on monocytes, an effect seen within 2 h.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted: 14 October 1997
Rights and permissions
About this article
Cite this article
Wallace, P., Keler, T., Guyre, P. et al. FcγRI blockade and modulation for immunotherapy. Cancer Immunol Immunother 45, 137–141 (1997). https://doi.org/10.1007/s002620050416
Issue Date:
DOI: https://doi.org/10.1007/s002620050416